Consultation on the Reimbursement Committee's recommendation for glucosamine
The Reimbursement Committee has reassessed the reimbursement status of glucosamine-containing medicines. Glucosamine-containing medicines are used for the alleviation of painful osteoarthritis
The Reimbursement Committee recommends removing general conditional reimbursement for these medicines.
During the review, the Danish Medicines Agency has received written contributions from several stakeholders, which the Reimbursement Committee has included in its assessments.
On 26 May 2011, the Danish Medicines Agency launched a consultation with the companies whose medicines are comprised by the Committee’s recommendations.
The consultation is open until 8 August 2011.
The relevant scientific societies and patient organisations as well as the Danish National Board of Health and the Institute for Rational Pharmacotherapy will be consulted concurrently.
Please find in the box to the right:
- The Reimbursement Committee's recommendation of 25 May 2011 (in Danish only)
- A copy of the Danish Medicines Agency's letter submitted to the companies (in Danish only)
- Stakeholder contributions (in Danish only)
- List of consulted scientific societies and patient organisations (in Danish only)